

- Albieri-Borges, A., 282
Aldrichi, J.M., 118
Aleem, M., 379
Alvarez, F., 122
Amaral, E., 45
Amir, O., 348
Anderson, F.D., 55
Antoniou, A.G., 362
Archer, D.F., 319
Ashok, P.W., 143, 327
Augusto, P.M., 74
- Bahamondes, L., 45
Bajos, N., 202
Balasinor, N., 379
Balasubramanian, S., 26
Balkus, J., 395
Bapu, C., 227
Barbieri, M., 118
Barer, T., 348
Barnhart, K.T., 357, 438
Basu, R., 458
Becker, D., 208
Beksinska, M.E., 170
Benedetto, C., 176
Berezowski, A.T., 309
Biron-Shental, T., 348
Björge, L., 231
Blackwell, R., 438
Blanchard, K., 474
Borges, M., 282
Bose, P., 282
Bouyer, J., 202
Brache, V., 122
- Cakir, L., 337
Caliskan, E., 337
Callahan, M.M., 443
Castilho, R.F., 130
Catalano, R., 263
Charnock-Jones, S., 239
Charnock-Jones, S.D., 263
Chattopadhyay, D., 372
Chen, K.-C., 153
Chen, M., 130
- Chen, P.L., 438
Chen, X.-L., 249
Cheung, E., 426
Chiang, H.-S., 153
Choudhari, J., 379
Chowdhury, S.R., 458
Christodoulakos, G.E., 362
Chuang, C.H., 157
Condon, S., 438
Cravioto, M.d.C., 451
Creatsas, G.C., 362
Creinin, M.D., 26, 333, 438, 447
Critchley, H., 31
Croxatto, H., 122
- da Silveira Rossi, A., 45
de Araújo, F.F., 118
de Freitas, T.G., 74
de Melo, N.R., 176
de Moura, M.D., 309
Dean, C., 122
Debaene, L., 421
Dede, F.S., 337
Denekens, J., 421
Díaz, J., 130
DiCenzo, R., 22
Dieben, T., 8
Dieben, T.O.M., 176
Dilbaz, B., 337
Dilbaz, S., 337
Dontas, I.A., 362
Duijkers, I., 8
Dungdung, S.R., 372
Dunlop, A.L., 188
Durand, M., 451
Düsterberg, B., 111
Dwivedi, A., 458
- Economou, E.V., 362
Eleftheriades, M.I., 362
Elliott, A., 95
Elomaa, K., 122
Endrikat, J., 111
Erdemoglu, E., 417
- Espey, E., 84
Evans, A., 239, 263
- Fagundes, M.L., 309
Fan, Y.S.S., 51
Farley, T.M.M., 170
Felix, J.C., 137
Feng, Q., 249
Fielding, S.L., 22
Findlay, J.K., 272
Fitzmaurice, A., 143
Flett, G.M.M., 143
Flett, G.M.M., 327
Fonsechi-Carvasan, G.A., 45
Frank, E., 188
Frank, H.-G., 282
Free, C., 426
Freeman, E.W., 104
Freund, K.M., 157
Funk, S., 319
- Gallo, M.F., 89, 162
Galvão, L.W., 130
Gao, F., 249
Gao, H.-J., 249
Garcia, S.G., 208
Gerlinger, C., 111
Ghosh, D., 294
Gill-Sharma, M., 379
Glasier, A., 31
Goldman, L., 208
Goldstein, H., 111
González-Macedo, J., 451
Goulard, H., 202
Goyal, N., 458
Gracia, C.R., 104
Gregoriou, O.V., 362
Greindl, A., 282
Griffin, D.P., 235
Grigorieva, V., 89
Grimes, D.A., 89, 161, 162
Guazzelli, C.A.F., 118
- Haberal, A., 337
Hahn, P.M., 197

- Hait, H., 55
 Hamoda, H., 143
 Hamoda, H., 327
 Hannaford, P., 95
 Harrison-Woolrych, M., 306
 Harwood, B., 26, 333, 447
 Hazzard, T.M., 239
 Heger-Mahn, D., 8
 Hill, R., 306
 Hsieh, H.-M., 153
 Hsiu, J., 55
 Hu, Z.-Y., 249
- Iversen, O.-E., 231
- Jackanicz, T.M., 122
 Jain, J.K., 137
 Jaisamram, U., 183
 Janssens, D., 465
 Jensen, J.T., 68, 79
 Jespersen, J., 111
 Jondet, M., 60
- Kang, W., 392
 Kaufmann, P., 282
 Kaunitz, A.M., 317
 Kayahan, A., 149
 Kelekçi, S., 417
 Kern, S.E., 402
 Kidd, A., 143
 Kim, D.-j., 130
 Kives, S., 197
 Kleinschmidt, I., 170
 Klipping, C., 8, 409
 Koistinen, H., 451
 Koistinen, R., 451
 Korver, T., 8
 Kouskouni, E.E., 362
 Kutluk, S., 417
- Lähteenmäki, P., 122
 Lambrinoudaki, I.V., 362
 Langan, E., 104
 Larrea, F., 451
 le Roux, P.A., 343
 Leeman, L., 84
 Leifels-Fischer, B., 176
 Letellier, B., 60
 Li, A., 137
 Lichenstein, R., 35, 40
 Lindsey, P.C., 118
 Lippes, J., 78
 Liu, K., 249
 Liu, L., 104
 Liu, Y.-X., 249
 Lo, S.S.T., 432
- Lo, S.T.S., 51
 Lohiya, N.K., 214
 Luoto, J., 438
 Lyritis, G.P., 362
- Macaluso, M., 130
 MacFarlane, S.A., 65
 Majumder, G.C., 372
 Makuch, M.Y., 45
 Malamud, D., 357
 Mandal, A.B., 372
 Manivannan, B., 214
 Marchi, N., 130
 Marr, J., 409
 Martens, M., 438
 Massai, R., 122
 Materi, H.L., 65
 Mauck, C., 443
 Mbatha, F., 170
 Mendes, M.C., 309
 Miller, L., 65, 395
 Miller, M.M., 319
 Minoo, P., 137
 Miranda, P., 122
 Mishell, D.R. Jr., 122, 304, 319
 Mishr, P.K., 214
 Montanari, T., 74
 Moreau, C., 202
 Morroni, C., 199
 Mountvarner, G., 35
 Mullen, P.D., 14
 Murphy, P.A., 402
 Murthy, A.S., 333, 447
- Nanda, K., 89, 162
 Nash, H., 122
 Nelson, A.L., 399
 Nelson, D.B., 104
 Neulen, J., 282
 Ng, W.L., 51
 Ngianga-Bakwin, K., 353
 Nie, G., 272
 Nivsarkar, M., 227
 Nucatola, D.L., 137
- Oddsson, K., 176
 Oliveira, L.C., 130
- Padh, H., 227
 Padwal, V., 379
 Parte, P., 379
 Patel, M., 227
 Patta, M.C., 309
 Peng, C.-C., 153
 Peremans, L., 421
 Perrea, D.N., 362
- Petta, C.A., 118
 Phupong, V., 474
 Plantinga, L.C., 40
 Poindexter, A., 319, 438, 443
 Pontrelli, G., 193
 Pötgens, A.J.G., 282
 Pretorius, E.S., 357
 Pruitt, S.L., 14
- Raptou, P.D., 362
 Raymond, E.G., 438
 Reid, R.L., 197
 Rethans, J.J., 421
 Rodrigues, R., 309
 Rodriguez, P., 302
 Rowe, P., 470
- Salamonsen, L.A., 272
 Sammel, M.D., 104
 Sangthawan, M., 1
 Santamato, S., 193
 Savan, K., 417
 Schaff, E.A., 22
 Schenken, R., 438
 Schmidt, J., 319
 Schmidt, W., 111
 Schmitz, S.W., 443
 Schreiber, C., 333
 Schreiber, C.A., 447
 Schultz, R., 188
 Schulz, K.F., 89, 162
 Schwartz, J.L., 443
 Schwinof, K.M., 68
 Scioscia, M., 193
 Selvaggi, L., 193
 Sengupta, J., 294
 Seppala, M., 451
 Shabbout, M., 357
 Sharkey, A.M., 263
 Shera, D., 357
 Shields, W., 81
 Shields, W.C., 302, 317, 399
 Shore, E., 26
 Shrivastava, N., 227
 Shulman, L.P., 81
 Siao, L.-J., 249
 Sivin, I., 122, 315
 Skouby, S.O., 111
 Small, M., 122
 Smit, J.A., 170
 Smith, S., 239
 Smith, S.K., 263
 Sneed, R., 199
 Sørensen, E.C.H., 231
 St. John, H., 31
 Stanczyk, F.Z., 197, 402

- Stones, R.W., 353
 Stouffer, R.L., 68, 239
 Suwikrom, S., 183
- Tan, K.H., 392
 Taneepanichskul, S., 1
 Tatum, C., 208
 Templeton, A., 143, 327
 Thompson-Graves, A.L., 55
 Tiezzi, L., 199
 Timbers, K., 357
 Todd, C.S., 35, 40
 Trussell, J., 315
 Tugrul, S., 149
 Tzenker, O., 348
- van Dam, J., 130
 van der Spuy, Z.M., 343
- van Osta, G., 8
 Van Royen, P., 421
 Vance, J.E., 68
 Verdys, M.-T., 60
 Verhoeven, C.H.J., 176
 Verhoeven, V., 421
 Vimercati, A., 193
 Vrijens, M., 465
- Wan, L., 438
 Wan, R.S.F., 432
 Wei, P., 249
 Wessel, J., 111
 Westhoff, C., 199
 Westhoff, C.L., 402
 Weyers, S., 465
 White, E., 197
 Wiel-Masson, D., 176
- Wilborn, W.H., 55
 Wildemeersch, D., 465, 470
 Williams, R.F., 55
 Winikoff, B., 474
 Wong, C.Y.G., 51
- Xiaoming, C., 316
 Xu, F., 239
 Xu, F.-H., 249
- Yavuzer, B., 149
 Yazlle, M.E.H.D., 309
 Yildirim, G., 149
 Ylmaz, B., 417
- Zampaglione, E., 319
 Zelinski-Wooten, M.B., 68
 Zou, R.-J., 249

Subject Index
Volume 71
January–June, 2005

Acceptability

- ACIDFORM gel vs K-Y® Jelly Personal Lubricant, 443
- copper-containing frameless IUCD, 51
- male vs female condoms, 130
- medical vs surgical abortion in the late first trimester, 143
- misoprostol+mifepristone in medical abortion, 447
- Nestorone®+ethinylestradiol vaginal rings, 122
- nonoxynol-9 spermicides, 438

- ACIDFORM gel vs K-Y® Jelly Personal Lubricant, penile irritation, 443

- Advance provision of EC pills, 432

Adverse effects

- ACIDFORM gel vs K-Y® Jelly Personal Lubricant, 443
- Implanon™, 319
- low-dose estrogen, review, 162
- Nestorone®+ethinylestradiol vaginal rings, 122
- nonoxynol-9 on human endometrium, 137

- Alstonia macrophylla* leaf extract, sperm immobilization (goat, human), 372

Angiogenesis

- postcoital contraception, 263
- related molecules, embryo implantation (monkey, mouse), 249

- Angiopoietin-2, effects on ovarian function (monkey), review, 239

- Antiphospholipid antibodies and contraception by inhibition of trophoblast fusion, 282

- Antiswarming activity on *Proteus* species, effect of *Alstonia macrophylla* leaf extract, 372

- Apoptosis-related molecules, and embryo implantation (monkey, mouse), 249

- Association of Reproductive Health Professions (ARHP) editorial

- contraceptive equity and access in the United states, 317
- health sexuality, 399

- religion and reproductive health, 302
- role of genetics in contraception and women's health, 81

- Attitudes and knowledge towards EC, 432

- Authorship change in recently published paper, 474

- Beck Depression Inventory after tubal ligation, 417

- Bilateral tubal ligation, effect on sex hormone levels and menopausal symptoms, 104

- Bioavailability of oral vs vaginal administration of Yuzpe and levonorgestrel in EC, 197

- Birth intervals in Sub-Saharan Africa, effect of reversible contraception, 353

- Blastocyst implantation failure and endometrial changes, effects of *Hibiscus rosa-sinensis* leaf extract, 227

Bleeding pattern

- effect of drug interaction of OC and St. John's Wort, 402
- effect of Implanon™, 319

- effect of Nestorone®+ethinylestradiol vaginal rings, 122
- low-dose estrogen, review, 162

- Bone mass accrual, effect of OC (rat), 362

- Bone mineral density, effect of DMPA, NET-EN, and combined oral contraceptive, 170

- Buccal vs. sublingual administration, misoprostol, 22

- C-telopeptides of collagen type I serum levels, effect of desogestrel+ethinylestradiol (rat), 362

- Calbindin expression in endometrium, relation to postcoital contraception, 272

Carbohydrate metabolism

- effect of ethinylestradiol+drospirenone vs ethinylestradiol+desogestrel, 409

- effect of oral ethinylestradiol+levonorgestrel dose reduction on, 111

- Cerazette®, maintenance of ovulation inhibition, 8

- Cervical dilatation, vaginal vs oral misoprostol

- C31G vaginal gel distribution, MRI evaluation, 357

- Cholesterol and triglyceride levels, effect of oral ethinylestradiol+gestodene, 118

- Chromatin condensation, effect of CPA (rat), 379

- Clinical performance, copper-containing frameless IUCD, 51

- Colorectal cancer risk in relation to oral contraception and HRT, 95

- Compliance, NuvaRing vs levonorgestrel+ethinylestradiol, 176

- Computer-assisted image analysis, endometrial microvessels, 60

- Condom effectiveness, male vs female, 130

- Consultation about oral contraception, performance of general practitioners, 421

- Contraception and women's health, role of genetics in, ARHP editorial, 81

- Contraceptive agents
 equity and access in the United states, ARHP editorial, 317
 male, steroid hormones, 89
- Contraceptive failure of implanon, experience in
 Australia, 306
- Contraceptive implant localization, Norplant, soft tissue
 X-ray films, 392
- Contraceptive methods, WHO research initiative on, 235
- Contraceptive services, for ED population, 40
- Contraceptive side effects, Implanon™, 319
- Contraceptive use
 hormonal, decision making, 426
 IUD, 149
 oral, in relation to colorectal cancer risk, 95
 oral ethinylestradiol+gestodene, effect on cholesterol
 and triglyceride levels, 118
- Contraceptive vaginal ring, scanning electron microscopy, 65
- Copper-containing frameless IUCD, acceptability and
 clinical performance in Hong Kong, 51
- Corpus luteum, molecules related to angiogenesis,
 proteolysis and apoptosis, and embryo implantation
 (monkey, mouse), 249
- Costs, medical abortion, mifepristone+misoprostol vs.
 misoprostol alone, 26
- CPA (cyproterone acetate)
- Cyproterone acetate (CPA) reduces spermatidal protamine
 (rat), 379
- Cytokine expression, effect of nonoxynol-9, 137
- Death, risk in mifepristone medical abortion, 161
- Decision making regarding use of hormonal
 contraceptive, 426
- Delayed tablet intake, desogestrel-only pill Cerazette®, 8
- Depot-medroxyprogesterone acetate (DMPA)
 effect on birth intervals in Sub-Saharan Africa, 353
 effect on bone mineral density, 170
 initiation of injection, 99
 same-day administration protocol, 395
- Depression after tubal ligation, 417
- Desogestrel, effect on voice quality, 348
- Desogestrel+ethinylestradiol
 effect on bone mass accrual (rat), 362
 effect on lipid and carbohydrate metabolism, vs
 ethinylestradiol+drospirenone, 409
- Desogestrel-only pill, maintenance of ovulation inhibition, 8
- Discontinuation, low-dose estrogen, review, 162
- Dissatisfaction and regret after tubal ligation, 417
- DMPA (depot-medroxyprogesterone acetate)
- Dose reduction
 oral estrogen, review, 162
 oral ethinylestradiol+levonorgestrel, effect on lipid and
 carbohydrate metabolism, 111
- Drospirenone, effect on voice quality, 348
- Drospirenone+ethinylestradiol vs ethinylestradiol+
 desogestrel, effect on lipid and carbohydrate
 metabolism, 409
- Drospirenone (DRSP), effects on premenstrual symptoms, 1
- DRSP (drospirenone)
- Drug interaction of OC with St. John's Wort, 402
- Drug serum levels during use of Nestorone®+
 ethinylestradiol vaginal rings, 122
- EC (emergency contraception)
- ED (emergency department)
- EE (ethinyl estradiol)
- Effectiveness
 gemeprost for termination of pregnancy, 193
 low-dose estrogen, review, 162
 male vs female condoms, 130
 Nestorone®+ethinylestradiol vaginal rings, 122
 oral vs vaginal misoprostol for cervical dilatation, 337
 trilostane prior to misoprostol in medical abortion, 343
- Efficacy
 Femilis™ levonorgestrel-releasing IUS, 465
 Implanon™, 319
 misoprostol+mifepristone in medical abortion,
 327, 333
 NuvaRing vs levonorgestrel+ethinylestradiol, 176
 steroid hormones as male contraceptive agents, 89
- Emergency contraception (EC)
 bioavailability of vaginal vs oral administration of
 levonorgestrel and Yuzpe, 197
 inaccurate descriptions in newspaper articles,
 1992-2002, 14
 knowledge, use and attitudes, 432
 knowledge among women, 157
 knowledge and pregnancy risk perception, 202
 levonorgestrel mechanism of action, 451
 mifepristone (monkey), 294
- Emergency department (ED)
 primary care services, 40
 unintended pregnancy risk, 35
- Endometrium
 angiogenic gene expression in, relation to postcoital
 contraception, 263
 changes and blastocyst implantation failure, effects of
Hibiscus rosa-sinensis leaf extract, 227
 effect of nonoxynol-9, 137
 embryo implantation, and molecules related to
 angiogenesis, proteolysis and apoptosis (monkey,
 mouse), 249
 glycodeclin-A levels, effect of levonorgestrel, 451
 microstructure, after long term use of 91-day extended-
 cycle OC regimen, 55
 mRNA and protein expression in, relation to postcoital
 contraception, 272
 vascularization, effects of levonorgestrel IUS use, 60
 vasculature, effects of vasotropic antihormone agents
 (monkey), 294
- Estradiol, effect of ormeloxifene (rat), 458
- Estrogen action, effect of ormeloxifene (rat), 458
- Estrogen oral contraceptive, dose reduction, review, 162

- Ethinyl estradiol+desogestrel, effect on bone mass accrual (rat), 362
- Ethinyl estradiol+drospirenone vs ethinylestradiol+desogestrel, effect on lipid and carbohydrate metabolism, 409
- Ethinyl estradiol+gestodene, effect on cholesterol and triglyceride levels, 118
- Ethinyl estradiol+levonorgestrel
 bioavailability of oral vs vaginal administration, 197
 dose reduction, effect on lipid and carbohydrate metabolism, 111
 low-dose, vs IUD, metabolic effects, 183
 vs NuvaRing, efficacy and safety, 176
- Ethinyl estradiol+Nestorone® vaginal rings, 122
- Ethinyl estradiol+progestin, decreased duration of hormone-free interval in low-dose formulations, 304
- Ethinyl estradiol (EE)
 effects on endometrial microstructure, 55
 pharmacokinetics, effect of St. John's Wort, 402
- Etonogestrel implant
 subdermal, Implanon™, safety and efficacy, 319
 and unintended pregnancy risk in Australia, 306
- Extended-cycle OC regimen, effects on endometrial microstructure, 55
- Female sterilization, transcervical polidocanol, 78
- Female vs male condoms, effectiveness, 130
- Femilis™
 effect on menstrual blood loss, 470
 efficacy and safety, 465
- Femilis™ levonorgestrel-releasing IUS
 effect on menstrual blood loss, 470
 efficacy and safety, 465
- Fertility, effect of CPA (rat), 379
- Fetal malformations, and termination of pregnancy failure, 231
- Follicle-stimulating hormone (FSH) serum levels, effect of CPA (rat), 379
- FSH (follicle-stimulating hormone)
- Gemeprost for termination of pregnancy, safety and effectiveness, 193
- General practitioners' performance on contraception consultation, 421
- Genetics, role in contraception and women's health, ARHP editorial, 81
- Gestation, late first trimester,
 medical vs surgical abortion, 143
 safety and efficacy of medical abortion, 327
- Gestodene, effect on voice quality, 348
- Gestodene+ethinylestradiol, effect on cholesterol and triglyceride levels, 118
- Glycodelin-A serum levels, effect of levonorgestrel, 451
- Gonadotropin-stimulated ovarian cycle, inhibition of oocyte maturation in rhesus macaques, 68
- GyneFix® 200 IUS and pregnancy rates, 315
- GyneFix/Ji Ni™, acceptability and clinical performance in Hong Kong, 51
- Healthy sexuality, ARHP editorial, 399
- Hibiscus rosa-sinensis* leaf extract, endometrial changes and blastocyst implantation failure, 227
- HIV infection, factors associated with reproductive options, 45
- Hong Kong, acceptability and clinical performance of copper-containing frameless IUCD, 51
- Hormonal contraception
 decision making regarding use, 426
 in males, 89
- Hormonal EC, levonorgestrel mechanism of action, 451
- Hormone-free interval of low-dose OC use, decreased duration, 304
- Hormone replacement therapy (HRT), in relation to colorectal cancer risk, 95
- HRT (hormone replacement therapy)
- HtrA3 expression in endometrium, relation to postcoital contraception, 272
- 17 β -Hydroxysteroid dehydrogenase activity, effect of ormeloxifene (rat), 458
- Hypericum perforatum* (St. John's Wort), drug interaction with OC, 402
- Immunogens and contraception, trophoblast fusion inhibition, 282
- Implanon™
 safety and efficacy, 319
 and unintended pregnancy risk in Australia, 306
- Implant contraceptive
 etonogestrel, and unintended pregnancy risk in Australia, 306
 Implanon™, safety and efficacy, 319
 in male hormonal contraception, 89
- Implant removal, Norplant, soft tissue X-ray films, 392
- Implantation
 effects of vasotropic antihormone agents (monkey), 294
 immunological inhibition of, 282
 research, WHO research initiative, 235
 role of molecules related to angiogenesis, proteolysis and apoptosis (monkey, mouse), 249
- Implantation failure of blastocyst, effects of *Hibiscus rosa-sinensis* leaf extract, 227
- Initiation of injectable DMPA, 99
- Injectable contraceptive
 depot-medroxyprogesterone (DMPA), 99
 DMPA, same-day administration protocol, 395
 effect on birth intervals in Sub-Saharan Africa, 353
 in male hormonal contraception, 89
- Insertion ease, Femilis™ levonorgestrel-releasing IUS, 465
- Interleukin 8 expression, effect of nonoxynol-9, 137
- Interleukin 1 β expression, effect of nonoxynol-9, 137
- Intrauterine device (IUD)

- copper-containing frameless, 51
- duration of use, discontinuation, and removal, 149
- effect on birth intervals in Sub-Saharan Africa, 353
- vs low-dose levonorgestrel+ethinylestradiol, metabolic effects, 183
- Intrauterine system (IUS), levonorgestrel-releasing, 60
 - effect on menstrual blood loss, 470
 - efficacy and safety, 465
- IUD (intrauterine device)
- IUS (intrauterine system)
- Journal publication, authorship change, 474
- K-Y® Jelly Personal Lubricant vs ACIDFORM gel, penile irritation, 443
- Knowledge
 - and attitudes towards EC use, 432
 - of EC among women, 157
 - of EC and pregnancy risk perception, 202
- Leaf extract
 - Alstonia macrophylla*, sperm immobilization (goat, human), 372
 - Hibiscus rosa-sinensis*, endometrial changes and blastocyst implantation failure, 227
- Leukemia inhibitory factor (LIF) monoclonal antibody, effects on endometrial vasculature (monkey), 294
- Levonorgestrel+ethinyl estradiol
 - bioavailability of oral vs vaginal administration, 197
 - dose reduction, effect on lipid and carbohydrate metabolism, 111
 - low-dose, vs IUD, metabolic effects, 183
 - vs NuvaRing, efficacy and safety, 176
- Levonorgestrel and Yuzpe in EC, bioavailability of vaginal vs oral administration, 197
- Levonorgestrel IUS, effects on endometrial vascularization, 60
- Levonorgestrel (LNG)
 - effects on endometrial microstructure, 55
 - effects on premenstrual symptoms, 1
 - mechanism of action, 451
- Levonorgestrel-releasing US, Femilis™
 - effect on menstrual blood loss, 470
 - efficacy and safety, 465
- LH (luteinizing hormone)
- LIF (leukemia inhibitory factor)
- Lipid metabolism
 - effect of ethinyl estradiol+drospirenone vs ethinylestradiol+desogestrel, 409
 - effect of oral ethinyl estradiol+levonorgestrel dose reduction on, 111
- Lipid peroxidation, effect of *Hibiscus rosa-sinensis* leaf extract, 227
- LNG (levonorgestrel)
- Localization of Norplant implant, soft tissue X-ray films, 392
- Long-term use of oral ethinylestradiol+gestodene, effect on cholesterol and triglyceride levels, 118
- Long-term vas occlusion with styrene maleic anhydride, safety of noninvasive reversal (monkey), 214
- Low drug dose
 - ethinyl lestradiol+levonorgestrel vs IUD, metabolic effects, 183
 - OC use and decreased duration of hormone-free interval, 304
 - oral estrogen, effectiveness, review, 162
- Luteal activity, effect of Nestorone®+ethinylestradiol vaginal rings, 122
- Luteinizing hormone (LH) serum levels, effect of CPA (rat), 379
- Magnetic resonance imaging (MRI), C31G vaginal gel distribution, 357
- Male condoms vs female condoms, effectiveness, 130
- Male hormonal contraception, steroid hormones, 89
- Malformations of the fetus, and termination of pregnancy failure, 231
- Manual vacuum aspiration
 - oral vs vaginal misoprostol for cervical ripening, 337
 - use in medical abortion, 84
- Mechanism of action, levonorgestrel EC, 451
- Medical abortion
 - acceptability and side effects of misoprostol+mifepristone, 447
 - inaccurate differentiation from EC in newspaper articles, 1992-2002, 14
 - mifepristone, manual vacuum aspiration, and obstetric ultrasound, 84
 - mifepristone+misoprostol, 327, 333
 - mifepristone+misoprostol vs. misoprostol alone, cost differential, 26
 - mifepristone use and risk of death, 161
 - trilostane prior to misoprostol, 343
 - of twin pregnancy with oral mifepristone, 231
 - vs surgical abortion in the late first trimester, 143
- Menopausal symptoms, effect of bilateral tubal ligation on, 104
- Menstrual blood loss, effect of Femilis™ levonorgestrel-releasing IUS, 470
- Meta-analysis
 - oral estrogen dose reduction, review, 162
 - steroid hormones as male contraceptive agents, 89
- Metabolic effects of low-dose ethinylestradiol+levonorgestrel vs IUD, 183
- Mexico, OC use and physician screening, 208
- Microarrays, identification of antiangiogenic agents for contraception, 263
- Microbicide safety and tolerability, ACIDFORM gel, 443
- Mifepristone
 - effects on endometrial vasculature (monkey), 294
 - in medical abortion of twin pregnancy, 231
 - in medical abortion risk of death, 161

- use in medical abortion, 84
- Mifepristone + misoprostol
 - costs for medical abortion, 26
 - medical abortion, 327, 333
 - in medical abortion, acceptability and side effects, 447
- Misoprostol
 - after trilostane administration in medical abortion, 343
 - costs for medical abortion, 26
 - oral vs vaginal administration, for cervical dilatation, 337
 - plasma concentrations, sublingual vs. buccal administration, 22
- Misoprostol + mifepristone
 - medical abortion, 327, 333
 - in medical abortion, acceptability and side effects, 447
- MNSF β (monoclonal nonspecific suppressor factor beta)
- Monoclonal nonspecific suppressor factor beta (MNSF β)
 - expression in endometrium, relation to postcoital contraception, 272
- Mortality risk in mifepristone medical abortion, 161
- MRI (magnetic resonance imaging)
- Mucin1 expression, effect of nonoxynol-9, 137
- Natural family planning methods, techniques, 188
- Nestorone[®] + ethinylestradiol vaginal rings, 122
- NET-EN (norethisterone enanthate)
- Newspaper articles, 1992-2002, inaccurate differentiation of medical abortion from EC, 14
- Nitric oxide synthase inhibitors, effects on endometrial vasculature (monkey), 294
- Noninvasive reversal after long-term vas occlusion, safety (monkey), 214
- Nonoxynol-9
 - effect on human endometrium, 137
 - spermicides, acceptability, 438
- Nonsurgical female sterilization, transcervical
- Norethindrone, pharmacokinetics, effect of St. John's Wort, 402
- Norethisterone enanthate (NET-EN), effect on bone mineral density, 170
- Norplant implant localization, soft tissue X-ray films, 392
- Nulliparous women, Femilis[™] levonorgestrel-releasing IUS, 465
- NuvaRing
 - scanning electron microscopy, 65
- NuvaRing
 - vs levonorgestrel + ethinylestradiol, efficacy and safety, 176
- Obstetric ultrasound, use in medical abortion, 84
- OC (oral contraceptive)
- Oocyte maturation
 - inhibition by PDE 3 inhibitor ORG 9935, 68
 - inhibition during gonadotropin-stimulated ovarian cycles in rhesus macaques, 68
- Oral administration
 - vs vaginal administration of levonorgestrel and Yuzpe, bioavailability, 197
 - vs vaginal misoprostol for cervical dilatation, 337
- Oral contraceptive (OC)
 - consultation, performance of general practitioners, 421
 - desogestrel + ethinylestradiol, effect on bone mass accrual (rat), 362
 - drospirenone vs. levonorgestrel, effects on premenstrual symptoms, 1
 - drug interaction with St. John's Wort, 402
 - effect on bone mineral density, 170
 - effect on voice quality, 348
 - ethinyl estradiol + progestin, decreased duration of hormone-free interval, 304
 - ethinylestradiol + drospirenone vs ethinylestradiol + desogestrel, effect on lipid and carbohydrate metabolism, 409
 - ethinylestradiol + gestodene, effect on cholesterol and triglyceride levels, 118
 - ethinylestradiol + levonorgestrel dose reduction, effect on lipid and carbohydrate metabolism, 111
 - levonorgestrel mechanism of action, 451
 - ormeloxifene, effect on estrogen, 17 β -Hydroxysteroid dehydrogenase, and progesterone receptor (rat), 458
 - in relation to colorectal cancer risk, 95
 - use in Mexico, physician screening, 208
 - vs IUD, metabolic effects, 183
 - vs NuvaRing, efficacy and safety, 176
- Oral estrogen dose reduction, review, 162
- ORG 9935, inhibition of oocyte maturation, 68
- Ormeloxifene, effect on estrogen, 17 β -Hydroxysteroid dehydrogenase, and progesterone receptor (rat), 458
- Osteoprotegerin serum levels, effect of desogestrel + ethinylestradiol (rat), 362
- Outcome measures comparison, SMSNV vs SNSV, 153
- Outcome of misoprostol + mifepristone in medical abortion, 327, 447
- Ovarian function
 - effect of drug interaction of OC and St. John's Wort, 402
 - effects of antiangiogenic agents (monkey), review, 239
- Ovarian hormone secretion, effect of tubal ligation, 309
- Over-the-counter sale of EC pills, 432
- Ovulation, detection techniques, 188
- Ovulation inhibition, desogestrel-only pill Cerazette[®], 8
- Parous women, Femilis[™] levonorgestrel-releasing IUS, 465
- Patient preference, medical vs surgical abortion in the late first trimester, 143
- PDE (phosphodiesterase)
- Penile irritation, effect of ACIDFORM gel vs K-Y[®] Jelly Personal Lubricant, 443
- Percutaneous vasectomy vs standard no-scalpel vasectomy (SNSV), outcome measures, 153
- Performance of general practitioners on contraception consultation, 421

- Perimenopausal women, metabolic effects of combined oral contraceptive vs IUD, 183
- Pharmacokinetics
buccal vs. sublingual misoprostol, 22
- Pharmacokinetics
norethindrone and ethinylestradiol, effect of St. John's Wort, 402
- Phosphodiesterase (PDE) 3 inhibitor ORG 9935, inhibition of oocyte maturation, 68
- Physician screening, OC use in Mexico, 208
- Pills in EC, knowledge, attitudes and use, 432
- Placentation, effects of vasotropic antihormone agents (monkey), 294
- Polidocanol, nonsurgical female sterilization, 78
- Postcoital contraception
angiogenesis, 263
endometrial targets for, 272
- Pregnancy
despite IUD, 149
despite Nestorone®+ethinylestradiol vaginal rings, 122
effect of *Ruta graveolans* (mouse), 74
interceptive effects of vasotropic antihormone agents (monkey), 294
- Pregnancy rates and GyneFix® 200 IUS, 315
- Pregnancy risk perception, and knowledge of EC, 202
- Premenstrual symptoms, effects of drospirenone vs. levonorgestrel, 1
- Primary care, for ED population, 40
- Progesterone receptor, effect of ormeloxifene (rat), 458
- Protein convertase 6 expression in endometrium, relation to postcoital contraception, 272
- Protamine gene expression, effect of CPA (rat), 379
- Proteolysis-related molecules, and embryo implantation (monkey, mouse), 249
- Proteus* species, antismoking effect of *Alstonia macrophylla* leaf extract, 372
- QS (quinacrine sterilization)
- Quinacrine sterilization (QS), 78
- Regret and dissatisfaction after tubal ligation, 417
- Religion and reproductive health, ARHP editorial, 302
- Removal of IUD, problems encountered during, 149
- Repeat TOP, risk factors, 31
- Reproductive health and religion, ARHP editorial, 302
- Reproductive practices, influencing factors among HIV-infected women, 45
- Resident training, medical abortion care in, 84
- Reversible contraception, effect on birth intervals in Sub-Saharan Africa, 353
- Rhesus macaques, inhibition of oocyte maturation during gonadotropin-stimulated ovarian cycles, 68
- Risk factors
more than one TOP, 31
- Risk factors
regret and dissatisfaction after tubal ligation, 417
- Risk of colorectal cancer in relation to oral contraception and HRT, 95
- Risk of death in mifepristone medical abortion, 161
- Risk perception of pregnancy, and knowledge of EC, 202
- Ruta graveolans*, effect on pregnant mice, 74
- Safety
ACIDFORM gel vs K-Y® Jelly Personal Lubricant, 443
ethinylestradiol+drospirenone vs ethinylestradiol+desogestrel, 409
Femilis™ levonorgestrel-releasing IUS, 465
gemeprost for termination of pregnancy, 193
Implanon™, 319
medical abortion using misoprostol+mifepristone, 327
Nestorone®+ethinylestradiol vaginal rings, 122
noninvasive reversal after long-term vas occlusion (monkey), 214
NuvaRing vs levonorgestrel+ethinylestradiol, 176
- Satisfaction after tubal ligation, 417
- SC35 splicing factor expression in endometrium, relation to postcoital contraception, 272
- Scanning electron microscopy, contraceptive vaginal ring, 65
- Semen exposure, male vs female condoms, 130
- Sex hormone levels, effect of bilateral tubal ligation on, 104
- Sexuality and health, ARHP editorial, 399
- Side effects
misoprostol+mifepristone in medical abortion, 447
trilostane prior to misoprostol in medical abortion, 343
vaginal vs misoprostol for cervical dilatation, 337
- Simply modified no-scalpel vasectomy (SMNSV) vs standard no-scalpel vasectomy (SNSV), outcome measures, 153
- Soft tissue X-ray films in localization of Norplant implant, 392
- Sperm count, effect of CPA (rat), 379
- Sperm immobilization effect of ursolic acid in *Alstonia macrophylla* leaf extract (goat, human), 372
- Spermatogenesis after noninvasive reversal of long-term vas occlusion (monkey), 214
- Spermicides, nonoxynol-9, acceptability, 438
- St. John's Wort, drug interaction with OC, 402
- Standard no-scalpel vasectomy (SNSV) vs simply modified no-scalpel vasectomy (SMNSV), outcome measures, 153
- Sterilization after tubal ligation, 417
- Steroid hormones, male contraceptive agents, 89
- Styrene maleic anhydride for vas occlusion, safety of noninvasive reversal (monkey), 214
- Sub-Saharan Africa, birth intervals in, effect of reversible contraception, 353
- Sublingual vs. buccal administration, misoprostol, 22
- Superoxide dismutase activity, effect of *Hibiscus rosa-sinensis* leaf extract, 227
- Superoxide radical activity, effect of *Hibiscus rosa-sinensis* leaf extract, 227

- Surgical abortion vs medical abortion in the late first trimester, 143
- Systematic review
- oral estrogen dose reduction, review, 162
 - steroid hormones as male contraceptive agents, 89
- Techniques in detecting ovulation, 188
- Termination of pregnancy (TOP)
- failure, and fetal malformations, 231
 - oral vs vaginal misoprostol for cervical dilatation, 337
 - second trimester, gemeprost, 193
 - trilostane prior to misoprostol, 343
 - women at risk for recurrence, 31
- Testosterone serum levels, effect of CPA (rat), 379
- TNP-470, effects on ovarian function (monkey), review, 239
- Tolerability
- ACIDFORM gel vs K-Y® Jelly Personal Lubricant, 443
 - Femilis™ levonorgestrel-releasing IUS, 465
 - NuvaRing vs levonorgestrel+ethinylestradiol, 176
- TOP (termination of pregnancy)
- Transcervical chemical sterilization, polidocanol, 78
- Transdermal contraceptive, in male hormonal contraception, 89
- Triglyceride and cholesterol levels, effect of oral ethinylestradiol+gestodene, 118
- Trilostane prior to misoprostol in medical abortion, 343
- Trophoblast fusion inhibition, immunologic, 282
- Tubal ligation
- bilateral, effect on sex hormone levels and menopausal symptoms, 104
 - effect on ovarian hormone secretion, 309
 - regret and dissatisfaction, 417
- Tumor necrosis factor α expression, effect of nonoxynol-9, 137
- Twin pregnancy, medical abortion with oral mifepristone, 231
- Unintended pregnancy risk
- ED population, 35
 - Unintended pregnancy risk
 - with etonogestrel implant, experience in Australia, 306
- Ursolic acid in *Alstonia macrophylla* leaf extract, sperm immobilization (goat, human), 372
- Vaginal administration
- vs oral administration of levonorgestrel and Yuzpe, bioavailability, 197
 - vs oral misoprostol for cervical dilatation, 337
- Vaginal contraception
- ACIDFORM gel vs K-Y® Jelly Personal Lubricant, 443
 - Nestorone®+ethinylestradiol, 122
- Vaginal gel distribution, C31G, MRI evaluation, 357
- Vaginal ring, NuvaRing, efficacy and safety, 176
- Vas occlusion with styrene maleic anhydride, safety of noninvasive reversal (monkey), 214
- Vascular endothelial growth factor (VEGF) antagonists, effects on ovarian function (monkey), review, 239
- Vascular endothelial growth factor (VEGF) monoclonal antibody, effects on endometrial vasculature (monkey), 294
- Vasectomy, comparison of methods and outcome measures, 153
- VEGF (vascular endothelial growth factor)
- Voice quality, effect of OC, 348
- WHO initiative on implantation research, 235
- WHO (World Health Organization)
- Women, knowledge on EC, 157
- Women's health and contraception, role of genetics in, ARHP editorial, 81
- X-ray films, soft tissue, localization of Norplant implant, 392
- Yuzpe and levonorgestrel in EC, bioavailability of vaginal vs oral administration, 197

